Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations.
暂无分享,去创建一个
[1] J. Freedman,et al. IgG‐mediated immunosuppression is not dependent on erythrocyte clearance or immunological evasion: implications for the mechanism of action of anti‐D in the prevention of haemolytic disease of the newborn? , 2007, British journal of haematology.
[2] F. Walther,et al. Neonatal Morbidity after Exchange Transfusion for Red Cell Alloimmune Hemolytic Disease , 2012, Neonatology.
[3] S. Stowell,et al. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. , 2013, Blood.
[4] M. Keller,et al. It's time to phase in RHD genotyping for patients with a serologic weak D phenotype , 2015, Transfusion.
[5] R. Rijnders,et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. , 2003, Transfusion medicine reviews.
[6] G. Daniels,et al. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell‐free fetal DNA in maternal plasma , 2007, Transfusion.
[7] Y. Brossard,et al. Quantitative determination of anti‐K (KEL1) IgG and IgG subclasses in the serum of severely alloimmunized pregnant women by ELISA , 2000, Transfusion.
[8] N. Avent,et al. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service , 2002, Transfusion.
[9] E. Hod,et al. Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. , 2012, Blood.
[10] G. Vidarsson,et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn , 2014, British journal of haematology.
[11] Intravenous immunoglobulin to treat neonatal alloimmune haemolytic disease , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.
[12] M. Murphy,et al. The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine , 2014, Transfusion.
[13] S. Stowell,et al. Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion , 2015 .
[14] B. Kumpel. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti‐D immunoglobulin: more questions than answers , 2007, Vox sanguinis.
[15] Kate C. Arnold,et al. Management of Alloimmunization During Pregnancy , 2017 .
[16] U. Cortes,et al. Mice Expressing RHAG and RHD Human Blood Group Genes , 2013, PloS one.
[17] C. Hillyer,et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells , 2006, Transfusion.
[18] C. Schoot,et al. Haemolytic disease of the fetus and newborn , 2015, Vox sanguinis.
[19] J. Hendrickson,et al. Clinically significant anti‐KEL RBC alloantibodies are transferred by breast milk in a murine model , 2016, Vox sanguinis.
[20] H. Nagaraja,et al. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. , 2015, American journal of obstetrics and gynecology.
[21] W. Flegel,et al. RHD gene deletion occurred in the Rhesus box. , 2000, Blood.
[22] P. Van de Perre. Transfer of antibody via mother's milk. , 2003, Vaccine.
[23] Wolfgang Friess,et al. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[24] F. Walther,et al. Hematological morbidity and management in neonates with hemolytic disease due to red cell alloimmunization. , 2011, Early human development.
[25] N. Rosenberg,et al. Persistent neonatal thrombocytopenia can be caused by IgA antiplatelet antibodies in breast milk of immune thrombocytopenic mothers. , 2015, Blood.
[26] Mark E. Williams,et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue , 2013, Journal of clinical apheresis.
[27] F. Klumper,et al. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. , 2007, American journal of obstetrics and gynecology.
[28] C. M. Cadwell,et al. Antigen loss from antibody-coated red blood cells. , 2009, Transfusion medicine reviews.
[29] S. Stowell,et al. Antigen Modulation Confers Protection to Red Blood Cells from Antibody through Fcγ Receptor Ligation , 2013, The Journal of Immunology.
[30] M. Keller,et al. Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype , 2015, Transfusion.
[31] Y. Brossard,et al. IgG1 and IgG3 anti‐D in maternal serum and on the RBCs of infants suffering from HDN: relationship with the severity of the disease , 2002, Transfusion.
[32] J. Zimring,et al. IgG-Mediated Immune Suppression to Erythrocytes by Polyclonal Antibodies Can Occur in the Absence of Activating or Inhibitory Fcγ Receptors in a Full Mouse Model , 2015, The Journal of Immunology.
[33] J. Zwaginga,et al. Extended matched intrauterine transfusions reduce maternal Duffy, Kidd, and S antibody formation , 2015, Transfusion.
[34] Martin L. Olsson,et al. The Blood Group Antigen Factsbook , 1997 .
[35] R. Mcconnell,et al. Experimental Studies on the Prevention of Rh Haemolytic Disease , 1961, British medical journal.
[36] R. Medzhitov,et al. The control of adaptive immune responses by the innate immune system. , 2011, Advances in immunology.
[37] K. Moise,et al. Management and Prevention of Red Cell Alloimmunization in Pregnancy: A Systematic Review , 2012, Obstetrics and gynecology.
[38] F. Walther,et al. Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus/newborn: the LOTUS study. , 2012, American journal of obstetrics and gynecology.
[39] R. Maier,et al. Prevention of immunization to D+ red blood cells with red blood cell exchange and intravenous Rh immune globulin , 2004, Transfusion.
[40] G. Daniels,et al. Causes of fetal anemia in hemolytic disease due to anti‐K , 2003, Transfusion.
[41] S. Hassan,et al. Combined plasmapheresis and intravenous immune globulin for the treatment of severe maternal red cell alloimmunization. , 2007, American journal of obstetrics and gynecology.
[42] M. Lindorfer,et al. Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. , 2015, Blood.
[43] K. Moise. Non-anti-D antibodies in red-cell alloimmunization. , 2000, European journal of obstetrics, gynecology, and reproductive biology.
[44] A. Shad,et al. Successful prevention of post‐transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD) , 1999, American journal of hematology.
[45] Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. , 2004, Pediatrics.
[46] G. Vidarsson,et al. Prophylactic anti‐D preparations display variable decreases in Fc‐fucosylation of anti‐D , 2015, Transfusion.
[47] W. G. Murphy,et al. Prevention of post‐transfusion RhD immunization using red cell exchange and intravenous anti‐D immunoglobulin , 2005, Vox sanguinis.
[48] J. Freedman,et al. Immunoglobulin G‐mediated regulation of the murine immune response to transfused red blood cells occurs in the absence of active immune suppression: implications for the mechanism of action of anti‐D in the prevention of haemolytic disease of the fetus and newborn? , 2008, Immunology.
[49] C. Hillyer,et al. IMMUNOHEMATOLOGY: Storage of murine red blood cells enhances alloantibody responses to an erythroid‐specific model antigen , 2009, Transfusion.
[50] A. Matson,et al. FcRn‐mediated intestinal absorption of IgG anti‐IgE/IgE immune complexes in mice , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[51] M. Delaney,et al. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. , 2015, Hematology. American Society of Hematology. Education Program.
[52] J. Bowman,et al. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? , 1985, American journal of obstetrics and gynecology.
[53] L. Platt,et al. Monocyte monolayer assay: an efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn. , 1989, American journal of clinical pathology.
[54] S. Stowell,et al. Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model , 2015, Haematologica.
[55] A. Eder. Update on HDFN: new information on long-standing controversies , 2006, Immunohematology.
[56] G. Vidarsson,et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. , 2014, Blood.
[57] N. Elbarbary,et al. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn—a prospective randomized controlled trial , 2011, European Journal of Pediatrics.
[58] A. Lazarus,et al. RhD Specific Antibodies Are Not Detectable in HLA-DRB1*1501 Mice Challenged with Human RhD Positive Erythrocytes , 2014, Advances in Hematology.
[59] I. Roberts,et al. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. , 1998, The New England journal of medicine.
[60] ACOG Practice Bulletin No. 75: Management of alloimmunization during pregnancy. , 2006, Obstetrics and gynecology.
[61] A. Lazarus,et al. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. , 2009, Hematology. American Society of Hematology. Education Program.
[62] C. M. Cadwell,et al. Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity , 2011, Transfusion.
[63] B. Kumpel. On the mechanism of tolerance to the Rh D antigen mediated by passive anti-D (Rh D prophylaxis). , 2002, Immunology letters.
[64] A. Hadley,et al. The ability of the chemiluminescence test to predict clinical outcome and the necessity for amniocenteses in pregnancies at risk of haemolytic disease of the newborn , 1998, British journal of obstetrics and gynaecology.